On March 19, 2010, Abraham, Fruchter & Twersky, LLP filed a class action lawsuit in the United States District Court for the District of Massachusetts (Case No. 10 Civ. 10470) on behalf of all investors who purchased or otherwise acquired the common stock of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG” or the “Company”) in the Company’s secondary public offering (“Secondary Offering”) on or about January 21, 2010.

The complaint, filed by Abraham, Fruchter & Twersky, LLP, is the only securities class action that has been commenced against the Company to preserve and protect the rights of AMAG investors. Other lawyers, however, who have not filed complaints of their own, continue to issue press releases, apparently for the sole purpose of soliciting clients.

AMAG investors who would like to speak with the attorneys who actually investigated and filed the AMAG securities class action should contact Abraham, Fruchter & Twersky, LLP, which has extensive experience in the prosecution of class actions on behalf of investors.

According to the complaint, the defendants made a series of misrepresentations and omissions that actively concealed and failed to disclose in the Registration Statement that users of the Company’s primary drug, Feraheme, had suffered adverse reactions, some requiring hospitalization. When the defendants revealed this information on February 4, 2010, AMAG’s stock plummeted over $7.00 per share.

If you would like to discuss this action or if you have any questions concerning this notice or your rights as a potential class member or lead plaintiff, you may contact: Jack Fruchter or Arthur J. Chen of Abraham, Fruchter & Twersky, LLP at 212-279-5050, or via e-mail at info@aftlaw.com or achen@aftlaw.com, respectively.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.